NCT02331498View on ClinicalTrials.gov

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

February 28, 2027

Study Completion Date

August 31, 2030

Conditions

Glioblastoma Multiforme

Interventions

DRUG

Pazopanib

Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.

Trial Locations (1)

06189

RECRUITING

Centre Antoine Lacassagne, Nice

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Centre Antoine Lacassagne

OTHER